Thoracic Oncology [especially non-small cell lung cancer (NSCLC), biomarker testing, precision treatment, targeted therapies, immunotherapy]

1.     Title: Participation in the IASLC Lung Cancer Staging Project  

Sponsor: International Association for Study of Lung Cancer (IASLC)

Time Period: 2020-25 (ongoing)

Role: Principal Investigator

2.     Title: To study the molecular mechanisms associated with resistance to EGFR and ALK inhibitors in patients with unresectable/metastatic non-squamous non small cell lung cancer (ns-NSCLC)  

Sponsor: Indian Council of Medical Research (ICMR)

Time Period: 2021-24 (ongoing)

Role: Principal Investigator

3.     Title: Evaluation of the effects of climate change on the epidemiology, baseline demographic and molecular characteristics of lung cancer

Sponsor: Department of Science & Technology (DST), Government of India

Time Period: 2017-21

Role: Principal Investigator

4.     Title: Evaluation of the prevalence of fibroblast growth factor receptor 1 (FGFR1) a potential novel therapeutic target in squamous cell carcinoma of lung and correlation of its expression with baseline demographic characteristics and with clinical outcomes

Sponsor: PGIMER, Chandigarh

Time Period: 2015-17

Role: Principal Investigator

5.     Title: Prognostic and predictive value of EGFR and KRAS mutations in non-small cell lung cancer

Sponsor: PGIMER, Chandigarh

Time Period: 2013-15

Role: Principal Investigator

6.     Title: ALK re-arrangement in non-small cell lung cancer: implications for treatment and tumor biology

Sponsor: PGIMER, Chandigarh

Time Period: 2013-15

Role: Co-Investigator

7.     Title: Immunochemistry and mutational analysis of FNAC samples as aids for histological and molecular typing of non-small cell lung cancer (NSCLC)

Sponsor: PGIMER, Chandigarh

Time Period: 2013-15

Role: Co-Investigator

8.     Title: Association of Single Nucleotide Polymorphisms and Methylation status in the Wnt and AhR signaling pathways with risk for occurrence of Lung Cancer in a North Indian Population

Sponsor: Indian Council of Medical Research (ICMR), New Delhi

Time Period: 2012-15

Role: Co-investigator

9. Title: Radiation therapy planning of Non-small Cell Lung Cancer based on PET/CT (Radiation oncology component)

Sponsor: International Atomic Energy Agency (IAEA), Vienna, Austria

Time Period: 2014-18

Role: Co-investigator

10. Title: Expression of predictive and prognostic biomarkers in tissue specimens of North Indian patients with lung cancer and their correlation with outcomes

Sponsor: Indian Council of Medical Research (ICMR), New Delhi

Time Period: 2012-13

Role: Co-investigator

11. Title: Assessment of health related quality of life in patients with lung cancer using generic and disease specific questionnaires

Sponsor: Indian Council of Medical Research (ICMR), New Delhi

Time Period: 2009-11

Role: Co-investigator

Dr. Navneet Singh was instrumental in initiating the multidisciplinary thoracic oncology team in 2009 with the support of faculty colleagues from different departments involved in lung cancer care. He remains its coordinator/convener till date. Dr. Singh, on behalf of the group, received the Lung Cancer Care Team Award of the International Association for Study of Lung Cancer (IASLC) at its World Conference on Lung Cancer at Barcelona (Spain) in September 2019. Moreover, Dr. Singh and his team were the winner not just from Asia-Pacific/Rest of World region but also Overall winner globally from all the 4 regions (North America, South America, Europe and Asia-Pacific/Rest of World). Subsequently,the entire PGIMER Multidisciplinary Lung Cancer Care Team was honored by Director PGIMER and other senior officials of the PGIMER administration by presenting individual IASLC Certificates of Excellence to team members.

Prof. Navneet Singh is one of the two individuals ever from the Asia-Pacific region to have been chairperson of American Society of Clinical Oncology's International Development and Education Award (IDEA) steering group as well as have received lifetime Fellowship of ASCO (FASCO) - the latter being conferred during the opening ceremony of the 2023 ASCO Annual Meeting at Chicago, USA. Also in 2023, he was conferred the Clifton Mountain Lectureship Award of IASLC in a plenary session of the World Conference on Lung Cancer at Singapore making him the first individual from South Asia to have received this honor.

International

• International Development and Education Award (IDEA) of the American Society of Clinical Oncology (ASCO) - 2008

• Fellowship of the American College of Chest Physicians (FCCP) - 2008

• Travel grant from the European Society for Medical Oncology (ESMO) for presenting research paper and attending European Multidisciplinary Congress in Thoracic Oncology at Lugano, Switzerland- 2009

• American Association for Cancer Research-National Cancer Institute (AACR-NCI) International Investigator Opportunity Grant - 2009

• Fellowship of the American College of Physicians (FACP) -2010

• Translational Research Unit (TRU) Visit Fellowship by ESMO -2010

• Travel scholarship from the Multinational Association of Supportive Care in Cancer (MASCC) for presenting research paper at International Symposium on Supportive Care in Cancer at Vancouver, Canada -2010

• Scholarship for presenting research paper at the 15^th World Conference on Tobacco Or Health (WCTOH) at Singapore - 2012

• Travel grant from ESMO for presenting research paper at the 3^rd European Lung Cancer Conference at Geneva, Switzerland - 2012

• Palliative Care Research Fellowship of ESMO - 2012/13

• Nominated Member, Publications Committee, International Association for Study of Lung Cancer (IASLC) for 2 successive terms (2013-15, 2015-17) 

• Travel grant from ESMO for Symposium on Immuno-Oncology at Geneva, Switzerland - 2013

• Travel grant from IASLC for oral research paper presentation at 2014 IASLC Asia Pacific Lung Cancer Conference (APLCC) at Kuala Lumpur, Malaysia

• Invited member of IDEA Steering Group of ASCO for a 7-year term (2014-21)

• Invited member of the Multidisciplinary Cancer Management Course (MCMC) Working Group of ASCO for a 3-year term(2015-18)

• Travel grant from ESMO for presenting research papers at the ESMO Asia 2015 Congress at Singapore

• Invited member of the Thoracic Cancer Guideline Advisory Group of ASCO for a 4-year term (2016-20)

• Travel grant from ESMO for Advanced Course on metastatic EGFR-mutant NSCLC at Seoul, South Korea - 2016

• Developing Nation Award at the IASLC’s 17th World Conference on Lung Cancer (WCLC) at Vienna, Austria - 2016

• Invited Member, Council of Regents, IASLC - 2016 onwards 

• Invited Member, Staging and Prognostic Factors Committee, IASLC - 2017 onwards

• Chair (2018-20) of IDEA Steering Group of ASCO

• Invited Member, Special Awards Selection Committee of ASCO (2019-22)

• Fellowship of Royal College of Physicians (London; FRCP) - 2019

• Invited Member, Membership Committee, IASLC - 2019 onwards

• Fellowship of the American Society of Clinical Oncology (FASCO) - 2023
• Clifton F. Mountain Lectureship Award of the International Association for Study of Lung Cancer (IASLC) - 2023

National

• Best Research Paper Award at 33rd convocation of Thapar Institute of Engineering and Technology (TIET), Patiala, India (2019). The research was collaboration between Dr. Navneet Singh, Department of Pulmonary Medicine, PGIMER, Chandigarh & Dr. Siddharth Sharma, Department of Biotechnology, TIET.

• Lung India Award of Indian Chest Society (ICS) for Outstanding Original Article for the year 2019 (role: corresponding author).

• Certificate of Appreciation for presenting high quality published research (Additional Professor category) on 7^th Annual Research Day of PGIMER - 2019

• 8^th Dr Reddy’s Oration on Lung Cancer of the Indian Society for Study of Lung Cancer - 2017

• Smt. Kamal Satbir Award of Indian Council for Medical Research - 2014

• Lung India Award for Best Referee by ICS - 2016

• Lung India Award for Prompt Referee by ICS thrice -2013, 2014 & 2017

• Elected Member of National Academy of Medical Sciences (NAMS) - 2014

• Certificate of Appreciation for presenting high quality published research (Assistant Professor category) on 3^rd Annual Research Day of PGIMER - 2014

• Certificate of Appreciation for presenting high quality published research (Assistant Professor category) on 2^nd Annual Research Day of PGIMER - 2013

• Fellowship of the Indian Chest Society (FICS) - 2011

• MBBS: Third in college in Second Professional examination

• MBBS:  Distinction in Physiology in First Professional examination

• Fellow of the American College of Physicians (ACP) – FACP

• Fellow of the American College of Chest Physicians (ACCP) – FCCP

• Life Member of the Indo-American Cancer Association (IACA)

• Full Member of the American Society of Clinical Oncology (ASCO)

• Member of the European Society for Medical Oncology (ESMO)

• Member of the International Association for the Study of Lung Cancer (IASLC)

• Memberof the American Association for Cancer Research(AACR)

• Member of the European Respiratory Society (ERS)

National

• Fellow of the Indian Chest Society (ICS) - FICS

• Elected Member of the National Academy of Medical Sciences (India) in 2014

• Life Member of the Indian Society for Study of Lung Cancer (ISSLC)

• Life Member of the Indian Cooperative Oncology Network (ICON)

• Life Member of the Molecular Oncology Society

• Life Member of the Immuno-Oncology Society of India (IOS-I)

• Life Member of the National College of Chest Physicians (India) – NCCP (I)

• Life Member of the Indian Association for Bronchology (IAB)

• Life Member of the Indian Society of Critical Care Medicine (ISCCM)

• Life Member of the Academy of Pulmonary Sciences, India

Select list of publications (related to thoracic oncology)

1. Singh N, Agarwal R, Aggarwal AN.             Quality-of-life assessment in trials of lung cancer. Lancet 2007; 370(9591): 933.

2. Singh N, Aggarwal AN. Quality of life as an endpoint of treatment efficacy in malignant lung tumours. Lancet Oncol 2008; 9(9): 820-821.

3. Singh N, Aggarwal AN. Docetaxel as second line therapy in advanced non-small cell lung cancer - the dose and combination may matter! J Thorac Oncol 2008; 3(9): 1078-1079.

4. Singh N, Aggarwal AN.Current approach to treatment of non-small cell lung cancer in developing countries – time for a rethink? J Thorac Oncol 2009; 4(1): 143-144.

5. Singh N, Aggarwal AN. Gefitinib plus docetaxel in non-small-cell lung cancer. Lancet 2009; 373(9663): 541-542.

6. Singh N, Aggarwal AN. ERCC1 and RRM1 expression in non-small cell lung cancer - the good, the bad and the unknown. J Thorac Oncol 2009: 4(8): 1042-1043.

7. Singh N, Srinivas R, Bal A, Aggarwal AN. Lung carcinoma mimicking hydatid cyst: a case report and review of the literature. Med Oncol 2009; 26(4): 424-428.

8. Singh N, Aggarwal AN, Gupta D, Behera D, Jindal SK. Unchanging clinico-epidemiological profile of lung cancer in North India over three decades. Cancer Epidemiol 2010; 34(1): 101-104.

9. Singh N, Aggarwal AN, Behera D, Jindal SK. Inter-cycle delays during chemotherapy of non-small cell lung cancer in a health-care resource constrained setting and their effect on overall survival. J Thorac Oncol 2010; 5(2): 236-239.

10. Singh N, Bal A, Aggarwal AN, Das A, Behera D. Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers. Future Oncol 2010; 6(5): 741-767.

11. Mootha VK, Agarwal R, Singh N, Aggarwal AN, Gupta D, Jindal SK. Medical thoracoscopy for undiagnosed pleural effusions: experience from a tertiary care hospital in north India. Indian J Chest Dis Allied Sci 2011; 53(1): 21-24.

12. Singh N, Aggarwal AN, Gupta D, Behera D. Prevalence of low body mass index among newly diagnosed lung cancer patients in North India and its association with smoking status. Thoracic Cancer 2011; 2(1): 27-31.

13. Singh N. Classification of large cell neuroendocrine carcinoma: at the cross roads of small and non-small cell lung cancer. J Thorac Oncol 2011; 6(7): 1298-1299.

14. Manohar K, Mittal BR, Kulkarni P, Singh N, Bhattacharya A, Gupta A. Usefulness of F-18 FDG PET/CT as One-Stop-Shop imaging modality for diagnosis of occult primary and estimation of disease burden in patients with intra-ocular masses. Clin Nucl Med 2012; 37(2): 200-203.

15. Singh N, Bal A. Lung cyst caused by centrally located bronchogenic carcinoma. Arch Bronconeumol 2012; 48(3): 88-91.

16. Singh N, Kulkarni P, Aggarwal AN, Mittal BR, Gupta N, Behera D, Gupta A. Choroidal metastasis as a presenting manifestation of lung cancer: a report of 3 cases and systematic review of the literature. Medicine (Baltimore) 2012; 91(4): 179-194.

17. Singh N, Aggarwal AN, Gupta D, Behera D, Jindal SK. Quantified smoking status and non-small cell lung cancer stage at presentation: analysis of a North Indian cohort and a systematic review of literature. J Thorac Dis 2012; 4(5): 474-484.

18. Singh N, Aggarwal AN, Behera D. Management of advanced lung cancer in resource constrained settings : a perspective from India. Expert Rev Anticancer Ther 2012: 12(11): 1479–1495.

19. Madan K, Singh N, Das A, Behera D. Pleural tuberculosis following lung cancer chemotherapy : a report of two cases proven pathologically by pleural biopsy. BMJ Case Rep 2013; DOI:10.1136/bcr-2012-008196, Published 22 January 2013.

20. Singh N, Goyal A. Lack of improvement in overall survival with gemcitabine/erlotinib maintenance and its relationship with pemetrexed use in the second line setting. J Clin Oncol 2013; 31(9): 1250-1251.

21. Goyal A, Singh N, Bal A, Behera D. Gynaecomastia, galactorrhoea, and lung cancer in a man. Lancet 2013; 381(9874): 1332

22. Kakkar N, Sakhuja V, Jindal SK, Singh N, Bal A, Sinha A. Pseudomesotheliomatous adenocarcinoma of lung: a diagnostic dilemma. J Postgrad Med Edu Res 2013; 47(2): 117-125. (DOI : 10.5005/jp-journals-10028-1068; accessible at http://www.jpmer.com)

23. Singh N, Mootha VK, Madan K, Aggarwal AN, Behera D. Tumor cavitation among lung cancer patients receiving first-line chemotherapy at a tertiary care centre in India: association with histology and overall survival. Med Oncol 2013; 30(3): 602.

24. Singh N, Madan K, Aggarwal AN, Gupta N, Das A, Behera D. Pleuro-pulmonary tuberculosis following chemotherapy for lung cancer at a tertiary care centre in India. J Postgrad Med Edu Res 2013; 47(4): 177-180. (DOI : 10.5005/jp-journals-10028-1082; accessible at http://www.jpmer.com)

25. Singh N, Behera D. Lung cancer epidemiology and clinical profile in North India: similarities and differences with other geographical regions of India. Indian J Cancer 2013; 50(4): 291.

26. Maturu VN, Singh N, Bansal P, Rai Mittal B, Gupta N, Behera D, Gupta A.Combination ofintravitreal bevacizumab and systemic therapy for choroidal metastases fromlung cancer: report of two cases and a systematic review of literature. Med Oncol. 2014; 31(4): 901.

27. Dhooria S, Singh N, Aggarwal AN, Gupta D, Agarwal R. A randomized trial comparing the diagnostic yield of rigid and semirigid thoracoscopy in undiagnosed pleural effusions. Respir Care 2014; 59(5): 756-764.

28. Bhoil A, Singh B, Singh N, Kashyap R, Watts A, Sarika S, Mittal BR. Can 3'-deoxy-3'-18F-fluorothymidine or 2'-deoxy-2'-18F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results. Hell J Nucl Med. 2014; 17(2): 90-96.

29. Singh N, Behera D. Palliation in metastatic non-small cell lung cancer: Early integration with standard oncological care is the key. Lung India 2014; 31(4): 317-319.

30. Singh N, Vishwanath G, Aggarwal AN, Behera D. Clinical experience on use of oral EGFR-TKIs as first-line treatment of advanced NSCLC from a tertiary care centre in North India and implications of skin rash. Indian J Chest Dis Allied Sci 2014; 56(3): 149-152.

31. Singh N, Jindal A, Behera D. Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature. World J Clin Oncol 2014; 5(5): 858-864

32. Singh N, Behera D. Lung cancer with cavitation – a distinct subgroup of NSCLC associated with worse overall survival. Respir Investig 2015; 53(3):133-134.

33. Maturu VN, Dhooria S, Bal A, Singh N, Aggarwal AN, Gupta D, BeheraD, Agarwal R. Role of medical thoracoscopy and closed blind pleural biopsy in undiagnosed exudative pleural effusions: A single centre experience of 348patients. J Bronchology Interv Pulmonol 2015;22(2): 121–129.

34. Singh N, Maturu VN, Behera D. Total Plasma Homocysteine Level Assessment and Timing ofFolate/B12 Supplementation Prior to Initiation of Pemetrexed Based Chemotherapyfor Non-Squamous NSCLC Patients – an Irrelevant Investigation or UnnecessaryDelay or Both? Oncologist 2015: 20: e21.

35. Sodhi KK, Bahl C, Singh N, Behera D, Sharma S. FunctionalGenetic Variants in pre-miR-146a and 196a2 genes are associated with risk oflung cancer in North Indians. Future Oncol 2015; 11(15): 2159-2173.

36. Sharma N, Singh A, Singh N, Behera D, Sharma S. Geneticpolymorphisms in GSTM1, GSTT1 and GSTP1 genes and risk of lung cancer in aNorth Indian population. Cancer Epidemiol2015; 39(6): 947-955.

37. Singh N, Bansal R, BeheraD, Gupta A. Intravitreal bevacizumab for choroidal metastases: the key to efficacy is simultaneous administration ofsystemic therapy. Eye 2015; 29(12):1629.

38. Singh N, Baldi M, Behera D. Inclusion of lymphangitis as a descriptor in the new TNM stagingof lung cancer : filling up the blank spaces. J Thorac Oncol 2015; 10(12): e119.

39. Koppaka D, Kapoor R, Bahl A,Bansal A, Mittal BR, Singh N. Impact of Integrating PET-CT in Radiotherapy Planning of Non-Small Cell Carcinoma Lung: Dosimetric and Radiobiological Comparison. J Integr Oncol 2015; 4(3): 139. [DOI:10.4172/2329-6771.1000139; accessible at www.omicsgroup.org/journals/integrative-oncology.php]

40. Singh N, Maturu VN, Sehgal IS, Kapoor R,Behera D. Clinical experience with oral topotecan in relapsed small cell lungcancer patients following irinotecan-platinum chemotherapy. J Postgrad Med Edu Res 2016; 50(2): 110-111. (accessible at http://www.jpmer.com)

41. Maturu VN, Singh N, Bal A, Gupta N, Das A, Behera D. Relationship of EGFR activating mutations with histologic subtyping according to IASLC/ATS/ERS 2011adenocarcinoma classification and their impact on overall survival. Lung India 2016; 33(3): 257-266.

42. Singh N, Singh PS, AggarwalAN, Behera D. Comorbidity assessment using CharlsonComorbidity Index and Simplified Comorbidity Score and its association withclinical outcomes during first-line chemotherapy of lung cancer. Clin Lung Cancer 2016; 17(3): 205-213.

43. Sehgal IS, Kaur H, Dhooria S,Bal A, Gupta N, Behera D, Singh N. Extrapulmonary small cell carcinoma of lymph node: Pooled analysis of all reported cases. World J Clin Oncol2016; 7(3): 308-320.

44. Girdhar Y, Singh N, Behera D, Sharma S. Combinations of the variant genotypes of CYP1A1, GSTM1 and GSTT1 are associated with an increased lung cancer risk in North Indian population: a case-control study. Pathol Oncol Res 2016; 22(3): 647-652.

45. Kaur H, Sehgal IS, Singh N.Chemotherapy regimens for metastatic non-small cell lung cancer : Generating good quality data is important before challenging evidence. Lung India 2016; 33(4): 470-472.
    

46. Chougule A, Bal A, Das A,Agarwal R, Singh N, Rao KLN. A Comparative Study of Inflammatory Myofibroblastic Tumors and TumefactiveIgG4-related Inflammatory Lesions: the Relevance of IgG4 Plasma Cells. Appl Immunohistochem Mol Morphol 2016;24(10): 721-728.

47. Kumari A, Bahl C, Singh N, Behera D, Sharma S. Association of p53codon 72 polymorphism and survival of North Indian lung cancer patients treatedwith platinum-based chemotherapy. Mol Biol Rep 2016; 43(12): 1383-1394.

48. Singh A, Singh N, Behera D, Sharma S. Association and multiple interaction analysis among five XRCC1polymorphic variants in modulating lung cancer risk in North Indian population.DNA Repair 2016; 47: 30-41.

49. Singh N, Prasad KT. A Cola to Improve My EGFR TKI Absorption in Metastatic Non–Small-Cell Lung Cancer? No, Thank You, I Prefer Lemonade or Orange Juice Instead. J Clin Oncol 2016; 34(33): 4053-4054.

50. Malik PS,Singh N. ASCENDing the anaplastic lymphoma kinase ladder: a tale of two C-nibs. JThorac Dis 2016; 8(11): E1514-E1516.

51. Girdhar Y, Singh N, Behera D,Sharma S. Synergistic association of CYP1A1polymorphisms with increased susceptibility to squamous cell lung cancer in north Indian Smokers. Int J Biol Markers 2016; 31(4):e402-e412.

52. Bahl C, Singh N, Behera D, Sharma S. Association of polymorphisms in the Dickopff (DKK) gene towards modulating risk for lung cancer in north Indians. Future Oncol 2017; 13(3):213-232.

53. Singh N, Aggarwal AN, Kaur J, Behera D. Association of graded folic acid supplementation and total plasma homocysteine levels with hematological toxicity during first-line treatment of non-squamous NSCLC patients with pemetrexed based chemotherapy. Am J Clin Oncol 2017; 40(1):75-82.

54. Singh PS, Aggarwal AN, Behera D, Kapoor R, Singh N. Simplified graded baseline symptom assessment in lungcancer patients undergoing first-line chemotherapy: correlations and prognosticrole in a resource constrained setting. JGlob Oncol 2017; 3(1): 54-63.

55. Kaur G, Nijhawan R, Gupta N, Singh N, Rajwanshi A. Pleural fluid cytology samples in cases of suspected lung cancer: An experience from a tertiary care centre. Diagn Cytopathol 2017; 45(3): 195-201.

56. Singh A, Singh N, Behera D, SharmaS. Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advancedNorth Indian lung cancer patientstreated with platinum-baseddoublet chemotherapy. Med Oncol 2017; 34(4): 64.

57. Bahl C, Sharma S, Singh N, Behera D. Association study between genetic variations in Axin2 gene and lung cancer risk in North Indian population: A multiple interaction analysis. Tumor Biol 2017; 39(4): 1010428317695533.

58. Baldi M, Behera D, Kaur J, Kapoor, Singh N. Rationale and Design of PEMVITASTART - an open-label randomized trial comparing simultaneous versus standard initiation of vitamin B12 and folate supplementation in non-squamous non-small cell lung cancer (NSCLC)patients undergoing first line pemetrexed-based chemotherapy. Clin Lung Cancer 2017; 18(4): 432-435.

59. Bahl C, Sharma S, Singh N,Behera D. Single nucleotide variationsin the Wnt antagonist sFRP3 (rs7775 & rs288326) and sFRP4 (rs1802073 &1802074) genes and their association with lung cancer risk in North Indians. Meta Gene 2017; 13: 159-168.

60. Yenge LB, Behera D, Garg M, Aggarwal AN, Singh N. Comparison of symptom score and bronchoscopy-based assessment with conventional computed tomography-based assessment of response to chemotherapy in lung cancer. J Glob Oncol 2017; 3(4): 370-379.

61. Singh N.Beyond EGFR and ALK testing in advanced non-small cell lung cancer - is the picture as 'ROS1'as it appears? LungIndia 2017;34(5): 405-408.

62. [Underthe aegis of Lung Cancer Consortium Asia (LCCA), Indian Cooperative Oncology Network (ICON), Indian Society of Medical & Pediatric Oncology (ISMPO),Molecular Oncology Society (MOS) and Association of Physicians of India (API)]. Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line. Indian J Cancer 2017;54(1): 89-103.

63. Singh N, Prasad KT. Practical solutions to epidermal growth factor receptor tyrosine kinase inhibitor dose modifications in resource constrained settings: thinking outside the (packaging) box. Indian J Cancer 2017; 54(1): 186-187.

64. Kaur H, Sehgal IS, Bal A, Gupta N, Behera D, DasA, Singh N. Evolving epidemiology of lung cancer in India: reducing non-small cell lung cancer-not otherwise specified and quantifying tobacco smoke exposure are the key. Indian J Cancer 2017; 54(1): 285-90.

65. Lawania S, Singh N, Behera D, Sharma S.Xeroderma pigmentosum complementation group D polymorphism toward lung cancer susceptibility survival and response in patients treated with platinum chemotherapy. Future Oncol 2017: 13(29): 2645–2665.

66. Sekar A, Gupta N, Rajwanshi A, Chaturvedi R, SinghN, Lal A. Role of the cytopathologist in subtyping and epidermal growth factor receptor testing in non-small cell lung cancer: an institutional experience. Cytopathology2017; 28(5): 371–377.

67. Radhakrishnan RK, Mittal BR, Gorla AKR, Basher RK,Sood A, Bal A, Kalra N, Khandelwal N, Singh N, Behera D. Real-timeintraprocedural 18F-FDG PET/CT-guided biopsy using automated robotic biopsy arm(ARA) in the diagnostic evaluation of thoracic lesions with prior inconclusive biopsy results : initial experience from a tertiary healthcare centre. Br J Radiol 2017; 90: 20170258. 

68. Bahl C, Singh N, Behera D, Sharma S.High-order gene interactions between the genetic polymorphisms in Wnt and AhRpathway in modulating lung cancer susceptibility. Per Med 2017; 14(6):487-502.

69. Bhardwaj A, BahlC, Sharma S, Singh N, Behera D. Interactive potential of genetic polymorphism inXenobiotic metabolising and DNA repair genes for predicting lung cancerpredisposition and overall survival in North Indians. Mutat Res 2018;826: 15–24.

70. Yogananda MN,Muthu V, Prasad KT, Kohli A, Behera D, Singh N. Utility of the Revised Edmonton Symptom Assessment System (ESAS-r) and the Patient Reported Functional Status (PRFS) in lung cancer patients. Support Care Cancer 2018; 26(3):767–775.

71. Sharma S, GuptaN, Singh N, Chaturvedi R, Behera D, Rajwanshi A. Cytomorphological features as predictors of epidermal growth factor receptor mutation status in lung adenocarcinoma. CytoJournal 2018, 15(1): 11.

72. Budhwar S, Bahl C, Sharma S, Singh N, Behera D. Role of sequence variations in AhR gene towards modulating smoking induced lung cancer susceptibility in North Indian population: A multiple interaction analysis. Curr Genomics 2018; 19(4): 313-326.

73. Lawania S, SinghN, Behera D, Sharma S. Association of XPA Polymorphisms Towards Lung CancerSusceptibility and its Predictive Role in Overall Survival of North Indians. Biochem Genet. 2018; 56(4): 375-396.

74. Lawania S, Sharma S, Singh N, BeheraD. XPF polymorphism toward lung cancer susceptibility and survival in patientstreated with platinum-based chemotherapy. Future Oncol 2018;14(11): 1071-1089.

75. Giroux DJ, VanSchil P, Asamura H, et al. The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. J Thorac Oncol 2018; 13(6):801-809.

76. Lawania S, Singh N, Behera D, Sharma S. XPC polymorphism and riskfor lung cancer in North Indian patients treated with platinum based chemotherapy and its associationwith clinical outcomes. Pathol Oncol Res 2018; 24(2): 353-366.

77. Singh A, Singh N, Behera D, Sharma S. Role of polymorphic XRCC6 (Ku70)/XRCC7 (DNA-PKcs) genestowards susceptibility and prognosis of lung cancer patients undergoingplatinum based doublet chemotherapy. MolBiol Rep 2018; 45(3): 253-261.

78. Kalemkerian GP,Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, Lew M, Pantelas J,Ramalingam SS, Reck M, Saqi A, Simoff M, Singh N, Sundaram B. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of AmericanPathologists/International Association for the Study of Lung Cancer/Associationfor Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol 2018; 36(9): 911-919.

79. Pandey A, Bahl C, Sharma S, Singh N, Behera D.Functional role of CyclinD1 polymorphism (G870A) in modifying susceptibilityand overall survival of North Indian lung cancer patients. Tumori 2018; 104(3): 179-187.

80. Bahl C, Singh N, Behera D, Sharma S.Genetic Variants in the Wingless Antagonist Genes (sFRP, DKK, and Axin2)Predict the Overall Survival and Prognosis of North Indian Lung Cancer PatientsTreated with Platinum-Based Doublet Chemotherapy. Cancer Biother Radiopharm2018; 33(10): 466-477 (DOI: 10.1089/cbr.2018.2491)

81. PrasadKT, Kaur H, Muthu V, Aggarwal AN, Behera D, Singh N. Interconversion oftwo commonly used performance tools: An analysis of 5844 paired assessments in1501 lung cancer patients. World J Clin Oncol 2018; 9(7): 140-147.

82. KumarR, Mittal BR, Bhattacharya A, Singh H, Bal A, Prakash G, Singh N.18F-FDG PET/CT-Guided Real-Time Automated Robotic Arm-Assisted NeedleNavigation for Percutaneous Biopsy of Hypermetabolic Bone Lesions: DiagnosticPerformance and Clinical Impact. Am J Roentgenol 2019; 212(1): W10-W18.

83. LawaniaS, Singh N, Behera D, Sharma S. XPG polymorphisms and their associationwith lung cancer susceptibility, overall survival and response in North Indianpatients treated with platinum-based doublet chemotherapy. Future Oncol2019; 15(2): 151-165.

84. Garg R, Bal A, Das A, Singh N, Singh H.Proliferation Marker (Ki67) in Sub-Categorization of Neuroendocrine Tumors ofthe Lung. Turk Patoloji Derg 2019; 35(1): 15-21.

85. Muthu V, Mylliemngap B, Prasad KT, Behera D, Singh N. Adverse effects observedin lung cancer patients undergoing first-line chemotherapy and effectiveness ofsupportive care drugs in a resource-limited setting. Lung India 2019;36(1): 32-37.

86. Singh N, Baldi M, Kaur J, et al. Timing of Folic Acid/Vitamin B12Supplementation and Hematologic Toxicity During First-Line Treatment ofPatients With Nonsquamous Nonsmall Cell Lung Cancer Using Pemetrexed-BasedChemotherapy: The PEMVITASTART Randomized Trial. Cancer 2019; 125(13):2203-2212.

87. Shankar A, Saini D, Dubey A, Roy S, Bharati SJ, Singh N, Khanna M, Prasad CP, Singh M, Kumar S, Sirohi B, Seth T, Rinki M, MohanA, Guleria R, Rath GK. Feasibility of lung cancer screening in developingcountries: challenges, opportunities and way forward. Trans Lung Cancer Res 2019; 8(Suppl 1): S106-S121.

88. Shankar A, Dubey A, Saini D, Singh M, Prasad CP,Roy S, Bharati SJ, Rinki M, Singh N, Seth T, Khanna M, Sethi N, Kumar S,Sirohi B, Mohan A, Guleria R, Rath GK. Environmental and occupationaldeterminants of lung cancer. Trans Lung Cancer Res 2019; 8(Suppl1): S31-S49.

89. Muthu V, Prasad KT, Singh N. Carboplatin dosing in real life: beyond estimating glomerular filtrationrate and the virtue of simplicity! Indian J Med Paediatr Oncol 2019;40(1): 155-157.

90. Singh A, Singh N, Behera D, Sharma S.Genetic Investigation of Polymorphic OGG1 and MUTYH Genes Towards IncreasedSusceptibility in Lung Adenocarcinoma and its Impact on Overall Survival ofLung Cancer Patients Treated with Platinum Based Chemotherapy. Pathol Oncol Res 2019; 25 (4): 1327-1340.

91. Singh A, Singh N, Behera D, Sharma S. XRCC1 632 as a candidate for cancer predispositionvia a complex interaction with genetic variants of base excision repair anddouble strand break repair genes. Future Oncol 2019; 15(33): 3845-3859.

92. Lawania S, SinghA, Sharma S, Singh N, Behera D. The multi-faceted high order polymorphicsynergistic interactions among nucleotide excision repair genes increase therisk of lung cancer in North Indians. Mutat Res 2019; 816-818: 111673.

93. Walia HK, VermaU, Singh N, Sharma S. Polymorphisms in GSTM1 and GSTT1 Influence theResponse and Treatment Outcome in Lung Cancer Patients Treated WithPlatinum-Based Chemotherapy. Br J Biomed Sci 2019; 76(4): 198-200.

94. Singh PK, Shrestha DK, Singh N, Gupta N. Extensive-disease small cell lung cancer,multiple relapses, five lines of therapy and more than 10-year survival. BMJ Case Rep 2020; DOI: 10.1136/bcr-2019-232607, Published 28 February 2020.

95. Edwards JG, Chansky K, Van Schil P, et al. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. J Thorac Oncol 2020;15(3): 344-359. 

96. Singh PK, Kumar R, Bal A, Gupta N, Kapoor R, Prasad KT, Singh N.Unearthing EGFR Mutations and the Rewards of Persistence in Precision Oncology:Breaching the 10-Year Survival Barrier in Metastatic NSCLC With Active Disease.JCO Global Oncol 2020; 6: 174-179.

97. Schneider BJ,Ismaila N, Aerts J, Chiles C, Daly ME, Detterbeck FC, Hearn JWD, Katz SI,Leighl NB, Levy B, Meyers B, Murgu S, Nekhlyudov L, Santos ES, Singh N,Tashbar J, Yankelevitz D, Altorki N. Lung Cancer Surveillance After DefinitiveCurative-Intent Therapy: ASCO Guideline. J Clin Oncol 2020; 38(7):753-766. 

98. Hanna NH, Schneider BJ, Temin S,Baker S, Brahmer J, Ellis PM, Gaspar LE, Haddad RY, Hesketh PJ, Jain D,Jaiyesimi I, Johnson DH, Leighl NB, Phillips T, Riely GJ, Robinson AG, RosellR, Schiller JH, Singh N, Spigel DR, Stabler JO, Tashbar J, Masters G.Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations:ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol 2020; 38(14):1608-1632. (DOI: 10.1200/JCO.19.03022).

99. Kumar S, Joga S, Biswas B, DabkaraD, Prasad KT, Singh N, Malik PS, Khurana S, Ganguly S, Muthu V, Batra U.Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India. Curr Probl Cancer 2020; 44(3): 100549(DOI: 10.1016/j.currproblcancer.2020.100549).

100. Prasad KT, Muthu V, Biswas B, MalikPS, Dabkara D, Ganguly S, Ghosh J, Kataria B, Khurana S, Verma S, Singh N.Utility and safety of maintenance chemotherapy in advanced non-small cell lungcancer across various performance status categories: real-world experience. CurrProbl Cancer 2020; 44(3): 100565 (DOI:10.1016/j.currproblcancer.2020.100565).

101. Garg A, Batra U, Choudhary P, JainD, Khurana S, Malik PS, Muthu V, Prasad KT, Singh N, Suri T, Mohan A. Clinical predictors of response to EGFR-tyrosine kinase inhibitors inEGFR-mutated non-small cell lung cancer: A real-world multicentric cohortanalysis from India. Curr Probl Cancer 2020; 44(3): 100570 (DOI:10.1016/j.currproblcancer.2020.100570).

102. Patel A, Batra U, Prasad KT, DabkaraD, Ghosh J, Sharma M, Singh N, Suresh P, Jain P, Malik PS, Choudhary P,Ganguly S, Khurana S, MS S, Bothra S, Muthu V, Biswas B. Real world experienceof treatment and outcome in ALK-rearranged metastatic nonsmall cell lungcancer: A multicenter study from India. Curr Probl Cancer 2020; 44(3):100571 (DOI: 10.1016/j.currproblcancer.2020.100571).

103. Singh N. Lung cancer in India: the rewards of REWERDS (REal World Evidence from RetrospectiveData analysis. Curr Probl Cancer 2020; 44(3): 100591 (DOI: 10.1016/j.currproblcancer.2020.100591).

104. Kapoor R, Das N, Miriyala R, Sood A, Oinam A, Singh N.Challenges of radical chemoradiation planning in Stage III non-small-cell lungcancer: Can volumetric modulated arc radiotherapy overcome an unfavourablelocation? Phys Imaging Radiat Oncol 2020; 13: 50–54.

105. Saxena P, Singh PK, Malik PS, Singh N. Immunotherapy Alone or in combination with Chemotherapy as First-Line treatment of Non-Small Cell LungCancer. Curr Treat Options Oncol 2020;21(8): 69 (DOI:10.1007/s11864-020-00768-2).

106. Singh N. Management of lung cancer during the COVID-19 pandemic:Practical solutions for resource-constrained settings from adaptions of aninternational consensus. Lung India 2020; 37(5): 381-383.

107. Soni S, Rastogi A, Prasad KT, Behera D, Singh N.Thyroid dysfunction in non-small cell lung cancer patients treated withepidermal growth factor receptor and anaplastic lymphoma kinase inhibitors:results of a prospective cohort. Lung Cancer 2021; 151(1): 16–19.

108. Hanna NH, Robinson AG, Temin S, Baker S Jr, Brahmer JR, EllisPM, Gaspar LE, Haddad RY, Hesketh PJ, Jain D, Jaiyesimi I, Johnson DH, LeighlNB, Moffitt PR, Phillips T, Riely GJ, Rosell R, Schiller JH, Schneider BJ, SinghN, Spigel DR, Tashbar J, Masters G. Therapy for stage IV non-small-celllung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol 2021; 39(9): 1040-1091.

109. Walia HK, SinghN, Sharma S. Association of NQO1Pro187Ser polymorphism with clinicaloutcomes and survival of lung cancer patients treated with platinumchemotherapy. Per Med. 2021; 18(4): 333-346.

110. Walia HK, Singh N,Sharma S. Genetic polymorphism of Arg213 His variant in the SULT1A1 gene isassociated with reduced susceptibility to lung cancer in North Indianpopulation. Xenobiotica 2021; 51(9): 1071-1080.

111. Kumari M, Singh P, SinghN, Bal A, Srinivasan R, Ghosh S. Identification and characterization ofnon-small cell lung cancer associated sialoglycoproteins. J Proteomics.2021; 248: 104336

112. Walia HK, Singh N,Sharma S. Genetic polymorphisms in the mEH gene in relation to tobacco smoking:role in lung cancer susceptibility and survival in north Indian patients withlung cancer undergoing platinum-based chemotherapy. Future Oncol. 2021;17(35): 4925-4946.

113. Garg G, Prasad KT, SinghN, Gupta P, Muthu V, Das A, Bal A. Programmed death-ligand 1 expression andtumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters. J Pathol Transl Med. 2021; 55(6): 398-405.

114. Sharma P, Singh N,Sharma S. ATP binding cassette transporters and cancer: revisiting thecontroversial role. Pharmacogenomics. 2021; 22(18): 1211-1235.

115. Gupta P, Bal A, Singh N. Comprehensive genomic profiling of lung cancer: A key to better clinicalmanagement. Cancer Res Stat Treat 2021; 4(4): 799-800.

116. Walia HK, Singh N,Sharma S. GSTP1 Ile¹⁰⁵Val polymorphismamong North Indian lung cancer patients treated using monotherapy andpoly-pharmacy. Hum Exp Toxicol. 2021; 40(12_suppl): S739-S752.

117. Saini KS, Martins-Branco D,Tagliamento M, Vidal L, Singh N, Punie K, Saini ML, Chico I, CuriglianoG, de Azambuja E, Lambertini M. Emerging issues related to COVID-19 vaccination in patients with cancer. Oncol Ther. 2021; 9(2): 255-265.

118. BandyopadhyayA, Sharma S, Behera D, Singh N. UGT1A1 gene polymorphisms in patientswith small cell lung cancer treated with irinotecan-platinum doubletchemotherapy and their association with gastrointestinal toxicity and overallsurvival. Oncologist. 2021; 26: 701-713.

119. Singh N, Agrawal S, Jiwnani S,Khosla D, Malik PS, Mohan A, Penumadu P, Prasad KT. Lung Cancer in India. J Thorac Oncol. 2021; 16(8): 1250-1266. DOI: 10.1016/j.jtho.2021.02.004

120. Rachagiri S, Gupta P, Gupta N, Rohilla M, Singh N, Rajwanshi A. Detection of ALK gene rearrangements in non-small celllung cancer by immunocytochemistry and fluorescence in situ hybridization oncytologic samples. Turk Patoloji Derg. 2022; 38(1): 16-24.

121. Walia HK, Singh N, Sharma S. Associationof NAT-2 gene polymorphisms toward lung cancer susceptibility and prognosis inNorth Indian patients treated with platinum-based chemotherapy. Pharmacogenomics.2022; 23(2): 97-118.

122. Daly ME, Singh N, Ismaila N, Antonoff MB,Arenberg DA, Bradley J, David E, Detterbeck F, Früh M, Gubens MA, Moore AC,Padda SK, Patel JD, Phillips T, Qin A, Robinson C, Simone CB. Management ofStage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol.2022; 40(12): 1356-1384.
     

123. Arora L, Kalia M, Dasgupta S, Singh N,Verma AK, Pal D. Development of a Multicellular 3D Tumor Model to StudyCellular Heterogeneity and Plasticity in NSCLC Tumor Microenvironment. FrontOncol. 2022; 12: 881207.

124. Detterbeck FC, Nishimura KK, Cilento VJ, et al.The International Association for the Study of Lung Cancer Staging Project:Methods and Guiding Principles for the Development of the Ninth Edition TNMClassification. J Thorac Oncol. 2022; 17(6): 806-815.

125. Walia H,Sharma P, Singh N, Sharma S. Predictive role of polymorphic variants ofphase II drug metabolising enzyme in modulating toxicity in North Indian lungcancer patients undergoing chemotherapy. Xenobiotica. 2022; 52(3):322-331.

126. Muthu V, Narasimhan RL, Prasad KT, Ahluwalia J, Garg M,Behera D, Singh N. Feasibility and impact of screening for venousthromboembolism in treatment-naïve lung cancer patients - results of aprospective cohort study. Indian J Cancer 2022;59: 203‑11.

127. Walia HK, Singh N, Sharma S. MTHFR polymorphism as apredictive biomarker for gastrointestinal and hematological toxicity in NorthIndian adenocarcinoma patients. J Chemother. 2022; 34(5): 326-340.

128. Ahlawat P, Phutela K, Bal A, Singh N,Sharma S. Therapeutic potential of human serum albumin nanoparticlesencapsulated actinonin in murine model of lung adenocarcinoma. Drug Deliv.2022; 29(1): 2403-2413.

129. Singh N, Temin S, BakerS Jr, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With DriverAlterations: ASCO Living Guideline. J Clin Oncol. 2022;40(28): 3310-3322.

130. Singh N, Temin S, BakerS Jr, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer Without DriverAlterations: ASCO Living Guideline J Clin Oncol. 2022;40(28): 3323-3343.

131. Shastri M, Gupta P, Gupta N, Singh N, BalA, Srinivasan R, Khosla D. Sequential small cell transformation and T790Mmutation in an epidermal growth factor-mutant lung adenocarcinoma: A rareoccurrence with significant management implications. Cytopathology 2022;33: 732–737.

132. Sharma P, Singh N, Sharma S. Polymorphismsin solute carrier genes (SLC19A1, SLCO1B1, and SLCO1B3) predicts survival andtoxicity in North Indian lung cancer patients undergoing platinum-based doubletchemotherapy. JClin Pharm Ther. 2022: 47(12): 2049-2067.

133. Singh S, Singh N, Sharma S. Genetic polymorphisms in themismatch repair pathway (MMR) genes contribute to hematological andgastrointestinal toxicity in North Indian lung cancer patients treated withplatinum-based chemotherapy. J Biochem Mol Toxicol. 2022; 36(11):e23183.

134. Sharma P, Singh N, Sharma S. Polymorphismin thymidylate synthase gene predicts survival and toxicity in north Indianlung cancer patients undergoing platinum-based doublet chemotherapy. Oncology.2022; 16(2): 69-82.

135. Singh S, Singh N, Baranwal M, Sharma S.Structural, functional analysis and association of MSH6 rs1800932, rs1042821polymorphisms with clinical outcome in North Indian lung cancer patientstreated with platinum-based doublet chemotherapy. Am J Med Sci. 2022;364(6):735-745.

136. Singh S, Singh N, Baranwal M, Sharma S.Association of MLH1-93G>A polymorphisms toward lung cancer susceptibilityand its association with clinical outcome in North Indian patients treated withplatinum-based chemotherapy. J Can Res Ther. 2023; 19: S397-403.

137. Sharma P, Singh N, Sharma S. Impact ofABCB1, ABCC1, ABCC2, and ABCG2 variants in predicting prognosis and clinicaloutcomes of north Indian lung cancer patients undergoing platinum-based doubletchemotherapy. J Gene Med. 2023; 25(1): e3460.

138. Lahiri A, Maji A, Potdar PD, Singh N,Parikh P, Bisht B, Mukherjee A, Paul MK. Lung cancer immunotherapy: progress,pitfalls, and promises. Mol Cancer 2023; 22(1): 40.

139. Owen DH, Singh N, Ismaila N, et al.Therapy for Stage IV Non–Small-Cell Lung Cancer without driver alterations:ASCO Living Guideline, Version 2022.2. J Clin Oncol. 2023; 41(5): e1-e9.

140. Owen DH, Singh N, Ismaila N, et al.Therapy for Stage IV Non–Small-Cell Lung Cancer with driver alterations: ASCOLiving Guideline, Version 2022.2. J Clin Oncol. 2023; 41(5): e10-e20.

141. Sharma P, Singh N, Sharma S. Geneticvariations in ABC transporter genes as a predictive biomarker for toxicity inNorth Indian lung cancer patients undergoing platinum‐based doublet chemotherapy. J Biochem Mol Toxicol. 2023; 37(3) :e23269.

142. JaiyesimiIA, Owen DH, Ismaila N, Blanchard E, Celano P, Florez N, Jain D, Singh N.Therapy for StageIV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO LivingGuideline, Version 2022.3. J Clin Oncol. 2023; 41(11): e21-e30.

143. Jaiyesimi IA, Owen DH, Ismaila N, BlanchardE, Celano P, Florez N, Jain D, Singh N. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.3. J Clin Oncol. 2023;41(11): e31-e41.

144. Asamura H, Nishimura KK,Giroux DJ, et al. IASLC Lung CancerStaging Project: The New Database to Inform Revisions in the Ninth Edition ofthe TNM Classification of Lung Cancer. J Thorac Oncol. 2023; 18(5):564-575.

145. Singh S, Sharma S, Lawania S, Singh N.Single-nucleotide polymorphisms of nucleotide excision repair genes and theirassociation with overall survival in North Indian lung cancer patients treatedwith platinum-based doublet chemotherapy. J Cancer Res Ther. 2023;19(2): 408-419.

146. Salifu I, Singh N,Berraondo M, et al. Antibody-drug conjugates, immune-checkpointinhibitors, and their combination in advanced non-small cell lung cancer. CancerTreat Res Commun. 2023; 36: 100713.

147. Damaraju V, Singh N, Garg M, Kathirvel S,Basher RK, Grover S, Kalra N, Prasad KT. Effect of prior pulmonary TB onlow-dose computed tomography during lung cancer screening. Int J Tuberc Lung Dis. 2023; 27(3): 223-225.

148. Mitsudomi T, Tan D, Yang JC, Ahn M, Batra U, ChoB, Cornelio G, Lim T, Mok T, Prabhash K, Reungwetwattana T, Ren S, Singh N,Toyooka S, Wu Y, Yang P, Yatabe Y. Expert consensus recommendations on biomarker testing in metastatic and nonmetastatic NSCLC in Asia. J Thorac Oncol. 2023; 18(4): 436-446.

149. Lam DC, Liam CK, Andarini S, Park S, Tan DSW, Singh N, et al. Lung Cancer Screening in Asia: An Expert Consensus Report. JThorac Oncol. 2023; 18(10): 1303-1322.

150. Singh N, Jaiyesimi IA, Ismaila N, et al. Therapyfor Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO LivingGuideline, Version 2023.1. J Clin Oncol. 2023 41(15): e42-e50.

151. Singh N, Jaiyesimi IA, Ismaila N, et al. Therapyfor Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO LivingGuideline, Version 2023.1. J Clin Oncol. 2023 41(15): e51-e62. Apr 6: JCO2300282. DOI: 10.1200/JCO.23.00282.

152. Singh N, Daly ME,Ismaila N. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2023; 41(27): 4430-4432.